Therefore, the result of this study suggested that the MIR4435-2HG/hsa-miR-1-3p/MMP9/hsa-miR-29-3p/DUXAP8 ceRNA network axis could be a potential target for immunotherapy in HCC. Here, DUXAP8 is linked to hepatocellular carcinoma.